NS 2389

Drug Profile

NS 2389

Alternative Names: GW 650250; GW 650250A

Latest Information Update: 15 Mar 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroSearch
  • Developer GlaxoSmithKline
  • Class Antidepressants; Butylene glycols
  • Mechanism of Action Adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 15 Mar 2002 Discontinued - Phase-II for Depression in United Kingdom (unspecified route)
  • 15 Mar 2002 Discontinued - Phase-II for Depression in USA (unspecified route)
  • 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top